Rocket Lab: Iridium Could Explode EBITDA, But A Wildcard Decides If It's Worth It
Rocket Lab canceled its $3.6 billion bridge loan without borrowing and says the Iridium deal is fully funded. The excerpt says Iridium's roughly $500 million in annual EBITDA could turn Rocket Lab's $80 million EBITDA loss into about $420 million before Neutron; up to 72 million new shares are expected, with 17 million tied to a collar stock-price window.
Why it matters — The deal's funding status, contribution to Rocket Lab's EBITDA, and potential share issuance are key details for Iridium watchers assessing the transaction.